US Vietnam Trade Deal Slashes Tariffs to 20 Percent Avoids Economic Clash
The United States announced a significant shift in its trade policy with Vietnam, reducing planned tariffs on Vietnamese exports to 20%, down from the initially proposed 46%, just days before a critical July 9 deadline. Former U.S. President Donald Trump revealed the agreement on Truth Social, calling it a “Great Honor” to finalize the deal with Vietnam’s leader, To Lam. The agreement marks a key moment in U.S.-Vietnam trade relations, as the two nations work to balance economic and strategic ties amidst ongoing tensions with China.
Vietnamese goods transshipped from third countries, such as China, will face a higher 40% tariff, reflecting U.S. concerns about mislabeled products. In exchange, Vietnam will offer zero tariffs on certain U.S. exports, including large-engine cars, further solidifying its trade relationship with Washington.
The deal comes as part of Trump’s ongoing tariff strategy, which has seen mixed results. While Britain and China reached limited agreements earlier, negotiations with other key partners, such as Japan and India, remain stalled. Vietnam’s agreement is seen as a political win for Trump, whose administration has faced challenges in completing major trade deals.
The U.S. has become Vietnam’s top export market, with Vietnamese exports to the U.S. tripling since 2018, reaching $137 billion in 2024. However, U.S. exports to Vietnam have grown far more modestly, increasing by only 30% to $13 billion. This stark imbalance has fueled tensions, particularly around transshipping, where goods largely made in China are re-labeled as Vietnamese.
The Vietnamese government celebrated the framework deal but did not confirm specific tariff levels. To Lam also urged Trump to recognize Vietnam as a market economy and lift restrictions on high-tech exports, longstanding demands from Hanoi.
Shares of major U.S. companies, including Nike and VF Corp, rose on news of the deal, highlighting its potential positive impact on American businesses. However, analysts warn that implementation challenges, particularly around the transshipment provision, could complicate the agreement’s success.
Vietnam has leveraged its growing trade relationship with the U.S. as a hedge against China, balancing its ties with the two superpowers. Experts believe that had the U.S. stuck to a 46% tariff, Vietnam’s trust in Washington would have been strained, potentially weakening their strategic and security cooperation.
As the July 9 deadline looms, more than a dozen countries are racing to negotiate similar deals. The U.S.-Vietnam agreement, while not a finalized trade pact, underscores the complex web of economic and political considerations shaping global trade in 2025.
Looking for chemical products? Let suppliers reach out to you!
2026-07-06
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Mounjaro Usage Doubles in June Sales Surge by 18 in India
-
Pharma Companies to See 11 Percent Growth in Sales and EBITDA in Q1FY26
-
Sipcam Nichino Brasil Unveils Soleado Fungicide at Hortitec 2025
-
Alchem Fined $576,000 for Role in EU Pharmaceutical Cartel
-
NHU and Sinopec Advance Liquid Methionine Project
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
Torrent Pharma Targets First Wave Semaglutide Launch Revenue Up 11 Percent as Patent Ends
-
Hengrui Strikes $500 Million Global Drug Deal with GSK Potential Payouts Up to $12 Billion
-
Lilly’s Mounjaro Enters China’s State Insurance System
Recommend Reading
-
Sun Pharma’s Winning Formula: Precision Over Expansion
-
Sun Pharma’s Secret Sauce: Solve the Specific, Win the Market
-
The Oral GLP-1 Cage Match: Orforglipron vs Rybelsus
-
Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28
-
Novo Nordisk Reports Theft of Six Drug Batches in India Authorities Warn of Severe Patient Safety Risks
-
Sulfuric Acid (H2SO4): Properties, Battery Uses, and Extreme Safety Hazards
-
What is Trametenolic Acid? (Structure, Sources & Research)
-
Redwall Raises Prices by as Much as 80%, Songwon Launches Global Increases, and Chemical Companies Are Collectively Passing On Costs
-
Advent Drops Its 2026 Purchase, and LANXESS’s €1.2 Billion Exit Plan Falls Through
-
Middle East Conflict Pushes Up Oil Prices as More Than 100 Chemical Raw Materials Rise in Concentration